Physician profile
Bruce Sokoloff
NPI 1639223746
$2,327.75
in general payments reported to CMS, 2019-2025
24 companies · $553 in 2025
The $553 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $283 · 2021: $373 · 2022: $144 · 2023: $194 · 2024: $381 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $623.65 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $515.57 | 2019-2025 | |
| Pfizer INC. | $266.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $157.79 | 2021-2025 | Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.32 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $95.65 | 2021-2025 | Veozah |
| Lilly USA, LLC | $92.27 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $58.58 | 2019-2025 | Otezla, Repatha, Otezla |
| Alexion Pharmaceuticals, INC. | $48.40 | 2024-2025 | Strensiq |
| Csl Behring | $44.94 | 2019-2021 | |
| Abbott Laboratories | $41.15 | 2024-2025 | Freestyle Libre 3 |
| Eisai INC. | $39.38 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.52 | 2019 | |
| Allergan, INC. | $27.38 | 2019-2020 | |
| Sanofi Pasteur INC. | $27.09 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $26.99 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $19.00 | 2023 | Quviviq |
| Acella Pharmaceuticals, LLC | $17.67 | 2024 | NP Thyroid 60 |
| Otsuka America Pharmaceutical, INC. | $17.59 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $14.90 | 2024 | Voquezna |
| Galderma Laboratories, L.P. | $14.85 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.77 | 2021 | |
| Alfasigma USA, INC. | $13.75 | 2020 | |
| Digestive Care, INC. | $13.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Sokoloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.